Nasdaq GlobeNewswire

Crown Bioscience Announces Collaboration to Develop Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Antibody


SANTA CLARA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces a collaboration to develop a CTLA-4 antibody with Jiangsu Qyun Bio-Pharmaceutical Co. Ltd.

As part of the collaboration agreement CrownBio will leverage Jiangsu Qyun Bio-Pharmaceuticals expertise to support the Investigational New Drug Application (IND) and further clinical development of CrownBio's proprietary 10B10 antibody.

"The collaboration agreement between CrownBio and Jiangsu Qyun Bio-Pharmaceutical Co. Ltd is indicative of our focus on innovation, and enhances our portfolio in immuno-oncology," said Jean-Pierre Wery, CEO of CrownBio. "Moreover, this partnership highlights CrownBio's commitment to develop therapies that could significantly impact the way cancer is treated."

10B10 is a humanized anti-CTLA-4 antibody with higher binding affinity and in vitro T cell stimulation than ipilimumab, the first immune checkpoint blockade antibody targeting CTLA-4 to receive FDA approval for the treatment of melanoma. The two antibodies have equivalent activity in T cell activation and tumor growth suppression but a different binding epitope and pharmacokinetic profile.

The goal of the collaboration between CrownBio and Jiangsu Qyun Bio-Pharmaceutical is to develop a less toxic CTLA-4 antibody and better combination strategies to overcome the immunological adverse effects due to T cell activation and proliferation observed in a minority of patients treated with anti-CTLA-4 immunotherapies.

"CrownBio is the ideal partner to progress candidate compounds to IND and clinical development thanks to their recognized in vivo pharmacology expertise and the high quality and standards of their operations, representing the perfect match to our knowhow in antibody engineering, cell line construction, and experience in GMP production management, quality control, clinical research, and regulatory affairs," said Qiu Jiwan CEO of Jiangsu Qyun Bio-Pharmaceuticals.

For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

About Jiangsu Qyun Bio-Pharmaceutical Co. Ltd                   

Jiangsu Qyun Bio-Pharmaceutical Co. Ltd was founded in June 2015 with registered capital of 90 million yuan. The company is focused in the development and production of antibody drugs.

The company's founding team is composed of both expat and domestic bio-pharmaceutical industry experts who have engaged in multiple successful monoclonal antibody drug development projects. Their expertise covers antibody engineering, cell line construction, process development, quality analysis and development, with extensive and rich experience in GMP production management, quality control, clinical research and regulatory affairs. Qyun adheres to the corporate philosophy of "science, conscience and dignity". Through the discovery and development of innovative antibody products the company's goal is to alleviate patient suffering while increasing patient dignity.

Media Enquiries:

Jody Barbeau
Crown Bioscience Inc.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Comodo CA Sees 35 Percent Year-Over-Year Increase in EV Certificates22.3.2018 15:47Pressemelding

EV SSL will be a topic of discussion at the Comodo CA booth during RSA 2018 CLIFTON, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Comodo CA, a worldwide leader in digital identity solutions, will address evolving cyberthreats and the increasing importance Extended Validation (EV) TLS/SSL certificates play in securing websites and inspiring consumer trust at the RSA Conference 2018, San Francisco, April 16 - 20. According to the Feb 2018 Netcraft report, Comodo CA has seen a 35 percent year-over-year increase of EV certificate units* making it one of the fastest growing providers of high assurance certificates. The volume of EV certificates globally also saw a record year in 2017 as more and more businesses adopt EV as standard practice for their websites. The demand for stronger, more secure EV certificates comes in the wake of increased phishing websites using Domain Validated (DV) certificates. Phishing websites imitate legitimate websites to steal customers' funds and identities. Phishi

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody22.3.2018 14:43Pressemelding

SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies. The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively. Under the terms of this global licensing agreement, CBT gain

Cloudflare Announces Mobile SDK to Monitor Network Performance for Applications22.3.2018 14:00Pressemelding

New free solution delivers network analytics to any mobile app developer SAN FRANCISCO, March 22, 2018 (GLOBE NEWSWIRE) -- Cloudflare, the leading Internet performance and security company, today announced the Cloudflare Mobile SDK, a free solution that enables any mobile app developer to understand network performance and metrics. Consumers are frustrated by mobile apps that are slow, crash, or deliver errors that degrade the user experience. For mobile app developers, a bad user experience means poor reviews, lower engagement, and reduced conversion on business metrics. Delivering consistent app performance requires focusing on every link in the chain: app code, network calls between the app and edge networks, and server infrastructure. There are a number of solutions that give developers analytics on their applications, but there has never been a way for app developers to understand how often their apps fail due to network errors. App developers easily integrate the Cloudflare Mobil

Compuware: Survey Shows Critical Mainframe Workloads Increasing While Mainframe Staff Losses Remain Unfilled22.3.2018 13:00Pressemelding

Many Organizations Not Measuring, Prioritizing Vital Key Performance Indicators 57 percent of enterprises with a mainframe currently run more than half of their business-critical applications on the platform-with that number expected to increase to 64 percent by next year. 72 percent of customer-facing applications are completely or very dependent on mainframe processing. Enterprises have only replaced 37 percent of the mainframe workforce lost over the past five years. Many organizations surveyed are not currently measuring velocity or efficiency key performance indicators, putting them at a disadvantage in the digital age. DETROIT, March 22, 2018 (GLOBE NEWSWIRE) -- The mainframe is becoming more important to large enterprises, with the percentage of organizations running at least half their business-critical applications on that platform expected to increase next year. However, the loss of skilled mainframe staff, and the failure to subsequently fill these positions, pose significan

SEMAFO: Construction of Boungou Mine 87% Complete22.3.2018 12:00Pressemelding

Dry Plant Commissioning Underway MONTREAL, March 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) is pleased to announce that construction of the Boungou Mine in Burkina Faso is 87% complete, with first gold scheduled to be poured early in the third quarter of 2018. In a first step towards this milestone, the Corporation began commissioning activities on dry plant equipment this week. All amounts are in US dollars unless otherwise stated. Over the coming weeks, as construction continues, the crushing and reclaim circuit equipment required for initial production will undergo testing. The power plant, which was over 90% complete at the end of February, has been partially operational since early March. As at February 28, 2018, the additional key achievements had been made: Development on budget with US$182 million of the US$231 million capital expenditure incurred Construction of the mine 87% complete Completion of some 94% of structural steel and mechanical installation Pipin

Lexin Appoints Two New Directors to Expand Board22.3.2018 02:49Pressemelding

SHENZHEN, China, March 22, 2018 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. ("Lexin" or the "Company") (NASDAQ:LX), a leading online consumer finance platform for educated young adults in China, today announced the appointment of Dr. Neng Wang as an independent director of the Company's board of directors (the "Board"), and the appointment of Mr. Xiaoguang Wu as a director of the Board, effective on March 20, 2018. These two appointments have expanded the Board to eight members, from six previously. Dr. Wang is also serving as a member of the audit committee, the compensation committee and the nominating and corporate governance committee of the Board. Dr. Wang has replaced Mr. Keyi Chen, Mr. Jared Yi Wu, and Mr. Yibo Shao respectively from the abovementioned committees of the Board, all of whom remain as directors on the Board. Dr. Wang has been Chong Khoon Lin Professor of Real Estate at Columbia Business School since July 2007, and a research associate at the National Bureau of E

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom